Skip to main content

Macrogenics Inc

MGNX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001125345

In the last 90 days, Macrogenics Inc insiders filed 0 open-market purchases and 1 sale; 122 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Macrogenics Inc changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of MGNX: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders137131−6
Shares58.4M60.0M+1.57M (+2.7%)
Value$419.1M$321.1M−$98.0M (−23.4%)

New holders (17)

Institutions that held Macrogenics Inc at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to MGNX in Q2 2023
InstitutionSharesValue% of portfolio
Woodline Partners LP364,700$1.95M0.02%
Sectoral Asset Management Inc352,497$1.89M0.31%
Vontobel Holding Ltd.352,497$1.89M0.02%
Wellington Management Group LLP241,305$1.29M0.00%
ClariVest Asset Management LLC97,600$522.0K0.03%
TD Asset Management Inc64,848$346.9K0.00%
Alps Advisors Inc45,453$243.2K0.00%
Balyasny Asset Management LLC35,062$187.6K0.00%
Exchange Traded Concepts, LLC23,534$125.9K0.00%
Graham Capital Management, L.P.21,427$114.6K0.00%
Captrust Financial Advisors16,116$86.2K0.00%
Prelude Capital Management, LLC13,374$71.6K0.01%
CI Private Wealth, LLC11,738$62.8K0.00%
ExodusPoint Capital Management, LP11,081$59.0K0.00%
Impact Partnership Wealth, LLC207$1.11K0.00%
National Bank of Canada190$1.01K0.00%
CWM, LLC90$00.00%

Sold out (23)

Institutions that held Macrogenics Inc at the end of Q1 2023 and filed for Q2 2023 without it.